Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-27T11:18:51.670Z Has data issue: false hasContentIssue false
  • English
  • Français

Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: the importance of assessing additional proarrhythmic risks

Published online by Cambridge University Press:  21 July 2014

Rohit S. Loomba ,
Anoop K. Singh ,
Joshua Kovach  and
Todd M. Gudausky
Rohit S. Loomba*
Affiliation:
Department of Cardiology, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America
Anoop K. Singh
Affiliation:
Department of Cardiology, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America
Joshua Kovach
Affiliation:
Department of Cardiology, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America
Todd M. Gudausky
Affiliation:
Department of Cardiology, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America
*
Correspondence to: Department of Cardiology, Children’s Hospital of Wisconsin, 9000 Wisconsin Avenue, Milwaukee, WI 53226, United States of America. Tel: 414-266-2600; Fax: 414-266-8517; E-mail: rloomba@chw.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Antiepileptic medications have been reported to cause disturbances in cardiac conduction. Lacosamide decreases seizure burden by modulating sodium channels. Although it has been demonstrated to have few side effects, there have been reports of clinically significant cardiac conduction disturbances. We report the case of a child with hypoplastic left-heart syndrome and well-controlled multifocal atrial tachycardia who developed haemodynamically significant atrial tachycardia after receiving two doses of lacosamide.

Keywords

Lacosamideatrial tachycardiavimpatflecainide
Type
Brief Reports
Information
Cardiology in the Young , Volume 25 , Issue 4 , April 2015 , pp. 806 - 809
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Casas-Fernandez, C, Martinez-Bermejo, A, Rufo-Campos, M, et al. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain. Drugs R&D 2012; 12: 187–197.Google Scholar
2. Verrotti, A, Loiacono, G, Pizzolorusso, A, et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 2013; 22: 210–216.Google Scholar
3. Chung, SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010; 3: 77–83.CrossRefGoogle ScholarPubMed
4. Chu-Shore, CJ, Thiele, EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol 2010; 17: 214–223.Google Scholar
5. Ben-Menachem, E, Biton, V, Jatuzis, D, Abou-Khalil, B, Doty, P, Rudd, GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308–1317.Google Scholar
6. Krause, LU, Brodowski, KO, Kellinghaus, C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav 2011; 20: 725–727.Google Scholar
7. Nizam, A, Mylavarapu, K, Thomas, D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia 2011; 52: e153–e155.Google Scholar
8. Degiorgio, CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010; 18: 322–324.CrossRefGoogle ScholarPubMed
9. Chinnasami, S, Rathore, C, Duncan, JS. Sinus node dysfunction: an adverse effect of lacosamide. Epilepsia 2013; 54: e90–e93.CrossRefGoogle ScholarPubMed
10. Shaibani, A, Fares, S, Selam, JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009; 10: 818–828.Google Scholar
11. Wymer, JP, Simpson, J, Sen, D, Bongardt, S. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009; 25: 376–385.Google Scholar
12. Wang, Q, Li, Z, Shen, J, Keating, MT. Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics 1996; 34: 9–16.Google Scholar
13. Crijns, HJ, van Gelder, IC, Lie, KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988; 62: 1303–1306.CrossRefGoogle ScholarPubMed
14. Randazzo, DN, Schweitzer, P, Stein, E, Banas, JS Jr., Winters, SL. Flecainide induced atrial tachycardia with 1:1 ventricular conduction during exercise testing. Pacing Clin Electrophysiol 1994; 17: 1509–1514.Google Scholar
15. Le Grand, B, Le Heuzey, JY, Perier, P, et al. Cellular electrophysiological effects of flecainide on human atrial fibres. Cardiovasc Res 1990; 24: 232–238.Google Scholar
16. Saetre, E, Abdelnoor, M, Amlie, JP, et al. Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia 2009; 50: 1841–1849.Google Scholar
17. Gavatha, M, Ioannou, I, Papavasiliou, AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2011; 20: 691–693.Google Scholar